ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study
The PERTINENT study measured biomarkers of atherosclerosis and thrombosis in a stable coronary artery disease population from EUROPA receiving ACE inhibition with perindopril 8 mg/day or placebo. Biomarkers of inflammation, C-reactive protein (CRP), fibrinogen, and tumor necrosis factor-alpha (TNF-α), and a biomarker of thrombosis, d-dimer, were measured at baseline and 1 year. CRP was recorded in 1157 patients; fibrinogen, TNF-α, and d-dimer in 291 patients. There was no significant effect of treatment on CRP or fibrinogen. In contrast, there were significant reductions in TNF-α (27.60-25.20 pg/mL; P < 0.05) and d-dimer (0.24-0.18 μg/mL; P < 0.05) with perindopril over 1 year. Survival analysis of the prognostic significance of baseline CRP failed to detect a significant role for the prediction of cardiovascular events over 4 years (lower versus higher tertile: 1.54; 95% confidence interval 0.88-2.68; P = 0.16). In conclusion, in the PERTINENT trial, we observed significant effects of ACE inhibition on biomarkers of the atherothrombotic complications (d-dimer) and the proinflammatory cytokine TNF-α, but not on biomarkers of inflammation associated with atherosclerosis (CRP and fibrinogen).
|Keywords||ACE inhibition, Coronary artery disease, Inflammation, Perindopril, Thrombosis|
|Persistent URL||dx.doi.org/10.1016/j.atherosclerosis.2008.08.042, hdl.handle.net/1765/14542|
Ceconi, C, Fox, K.M, Remme, W.J, Simoons, M.L, Deckers, J.W, Bertrand, M.E, … Ferrari, R. (2009). ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study. Atherosclerosis, 204(1), 273–275. doi:10.1016/j.atherosclerosis.2008.08.042